Cosmo NVCMOPF -3.22%82 Quick Ratio is 6.77 as of Dec. 2025, which is 32% below its 10-year median of 9.93. GuruFocus rates CMOPF with a GF Score™ of 82/100 and a GF Value™ of $54.86 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 997 Drug Manufacturers companies, Cosmo NV ranks better than 92.38% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Cosmo NV's quick ratio for the quarter that ended in Dec. 2025 was 6.77.
Cosmo NV has a quick ratio of 6.77. It generally indicates good short-term financial strength.
The historical rank and industry rank for Cosmo NV's Quick Ratio or its related term are showing as below:
CMOPF'
s Quick Ratio Range Over the Past 10 Years
Min: 1.51 Med: 9.93 Max: 24.13
Current: 6.77
During the past 13 years, Cosmo NV's highest Quick Ratio was 24.13. The lowest was 1.51. And the median was 9.93.
CMOPF's Quick Ratio is ranked better than 92.38% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs CMOPF: 6.77
Cosmo NV (OTCPK:CMOPF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Cosmo NV Quick Ratio Related Terms
Cosmo NV Quick Ratio Historical Data
* Premium members only.
The historical data trend for Cosmo NV's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Cosmo NV's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Cosmo NV's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Cosmo NV's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo NV (CMOPF) has a Quick Ratio of 6.77 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Cosmo NV and its competitors. This is 32% below median its historical median of 9.93. Over the past decade, Cosmo NV's Quick Ratio has ranged from 1.51 to 24.13. According to the industry distribution chart, Cosmo NV ranks #76 out of 997 companies in the Drug Manufacturers industry, placing it in the top 7.6%.
Is Cosmo NV's Quick Ratio too high?
Cosmo NV's current Quick Ratio of 6.77 is 32% below median its 10-year median of 9.93. Over the past 10 years, this metric has ranged from a low of 1.51 to a high of 24.13. The Drug Manufacturers industry median Quick Ratio is 1.45. Cosmo NV's value of 6.77 is 366.9% above this industry median. Based on the distribution chart, Cosmo NV ranks #76 out of 997 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cosmo NV has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Quick Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #76 out of 997 companies for Quick Ratio. This places Cosmo NV in the top 8% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. Cosmo NV's value of 6.77 is 366.9% above this benchmark. Historically, Cosmo NV's own Quick Ratio has ranged from 1.51 to 24.13 over the past decade. While the company's 10-year median is 9.93 vs. the industry median of 1.45, Cosmo NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current Quick Ratio of 6.77 is 366.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current Quick Ratio is 6.77, which is 32% below median its own 10-year median of 9.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $54.86, compared to a current price of $82.00 — trading 49.5% above its estimated fair value. The current Quick Ratio is 6.77, which is 32% below median its 10-year median of 9.93 and 366.9% above the Drug Manufacturers industry median of 1.45. Cosmo NV's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current Quick Ratio is 6.77 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (CMOPF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of $82.00 is trading 49.5% above its estimated GF Value™ of $54.86.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for CMOPF:
Quick Ratio: 6.77 (32% below median its 10-year median of 9.93)
GF Value™: $54.86 vs. price of $82.00 (49.5% above fair value)
Industry Position: 366.9% above the Drug Manufacturers median (#76 of 997)
No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
82GF Score
Get the complete analysis for CMOPF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMOPF has been successfully added to your 
